Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Obtains Exclusive Rights to Negotiate TriPath Acquisition

NEW YORK (GenomeWeb News) – Becton Dickinson has exclusive rights to negotiate an acquisition of TriPath Imaging, according to documents filed with the Securities and Exchange Commission yesterday.
As GenomeWeb News reported on Tuesday, Becton Dickinson offered  buy all outstanding TriPath shares for $9.25 each, or about $350 million. The company currently holds a 6.5-percent stake in TriPath.
According to the filing, the exclusive agreement is in place until Aug. 25. If TriPath violates the agreement, it will pay Becton Dickinson $5 million in termination fees.
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.